AI Revolutionizes Non-Alcoholic Steatohepatitis (NASH) Diagnosis and Treatment, Fueling Impressive 53.49% CAGR - ResearchAndMarkets.com
The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.
- The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.
- NASH, often referred to as "Silent Liver Disease," is a liver disorder caused by long-term alcohol abuse but mainly impacts non-alcoholics.
- It is the second stage of Non-Alcoholic Fatty Liver Disease (NAFLD), marked by liver inflammation and cell damage.
- As a result, there was an increased demand for NASH treatment, diagnostic tools, and emerging drugs, positively impacting the market.